Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that baricitinib was effective and well-tolerated over 52 weeks for severe alopecia areata, with significant improvements in disease severity and no serious adverse events.

This study found that administering 5 mg of oral minoxidil daily for 24 weeks led to a 20.3% increase in hair density among men with androgenetic alopecia, although side effects like hypertrichosis and hypotension were observed.

This prospective study reported that 5 mg daily oral low-dose minoxidil over 24 weeks led to a high prevalence of hypertrichosis in 93% of male androgenetic alopecia patients, particularly affecting younger individuals, but generally had minimal impact on patients’ quality of life.

In this study, creatine supplementation over 12 weeks showed no effect on androgen levels or hair follicle health in healthy young males, challenging the belief that creatine causes hair loss.

This study found that low-dose oral minoxidil effectively increased hair count over 24 weeks with mild reductions in blood pressure and minimal adverse effects among participants, suggesting its potential as a safe treatment for hair loss.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

This study found that a combination of probiotic strains of Lactiplantibacillus administered over 16 weeks reduced the number and density of telogen hairs in individuals with androgenic alopecia, while increasing the abundance of Lactobacillus in their gut microbiota.

This study found that using 'moha: 5-in-1' hair oil for 8 weeks significantly reduced hair fall, increased hair growth rate and thickness, and decreased scalp dandruff among healthy adults with alopecia, with no adverse effects reported.

This study found that baricitinib, taken for 24 weeks, significantly reduced alopecia severity in patients with moderate-to-severe alopecia areata, with 50% showing marked improvement and overall favorable safety and efficacy reported.

This study reports a case of complete hair regrowth in lichen planopilaris after 12 weeks of treatment with ixekizumab, suggesting its potential as a targeted therapy.

This study observed that using an aroma shampoo containing essential oils for 4 weeks improved hair density and number in the occipital area, unlike a general shampoo used by the control group, which led to decreased hair number and thickness in the parietal area.

This study found that patients with COVID-19 infection lasting longer than two weeks experienced more severe post-infection hair loss, with women and older individuals particularly affected.

This study demonstrated that an RO formulation significantly improved neck wrinkles after 8 weeks of application, compared to a placebo, in Japanese female subjects.

A new cosmetic cream reduced facial redness and skin temperature after 4 weeks of use.

This study found that zebrafish can completely regenerate their ventricular myocardium within four weeks, with Wnt/β-catenin signaling playing a critical role in cardiomyocyte dedifferentiation and proliferation.

This study discovered that TTR is expressed in the human placenta as early as 6 weeks gestation, with increased levels in the first trimester potentially facilitating thyroid hormone delivery to the fetus.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

This study found that applying topical minoxidil 5% twice daily for 24 weeks increased hair density and width in men with androgenetic alopecia, although the change in clinical hair grading was not statistically significant.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study found that a 2% topical minoxidil solution significantly increased hair regrowth compared to placebo in women with androgenetic alopecia over 32 weeks.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This study found that the EpiLight Hair Removal System achieved approximately 60% hair removal after 12 weeks following a single treatment, indicating effectiveness and safety for long-term hair reduction.

This study found that daily use of 1% pyrithione zinc shampoo modestly improved hair growth over 26 weeks, although these effects were less than those of 5% minoxidil.

This study found that micrografts containing human hair follicle mesenchymal stem cells significantly increased hair count and density compared to placebo over 58 weeks in patients experiencing hair loss.

This study found that topical calcipotriol may safely and effectively treat mild-to-moderate patchy alopecia areata, with significant hair regrowth observed in the majority of participants over 12 weeks.

This study found that topical valproic acid significantly increased hair count in male patients with moderate androgenetic alopecia compared to placebo over 24 weeks.

This study found that polymers significantly improved the chemical and microbial stability of steroid hormones in liposome formulations over eight weeks, with finasteride showing the highest diffusion rate.

This study found that St. John's wort treatment for two weeks induced finasteride metabolism and reduced its plasma exposure in healthy men.

In this controlled study, a pulsed electrical field treatment significantly increased hair regrowth compared to baseline and the control group over 36 weeks, without observed side effects.

This study found that normal-mode ruby laser treatment significantly improved facial hirsutism and maintained results for at least 48 weeks, with repeated treatments enhancing clinical effects.